Trials / Unknown
UnknownNCT04165174
PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT
A Single Arm, Observational Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment With PD-1 Monoclonal Antibody Plus Apatinib and SBRT in HCC With PVTT
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
It is a trial to assess the efficacy and safety of PD-1 monoclonal antibody plus Apatinib combined with SBRT as first-line treatment in HCC with PVTT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Terepril monoclonal antibody; Apatinib | Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD |
| RADIATION | SBRT | 6-10Gy/F,5-8F |
Timeline
- Start date
- 2019-12-01
- Primary completion
- 2020-11-01
- Completion
- 2020-12-01
- First posted
- 2019-11-15
- Last updated
- 2019-11-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04165174. Inclusion in this directory is not an endorsement.